Prognostic Stage IV Breast Cancer AJCC v8 Recruiting Phase 1 Trials for Pembrolizumab (DB09037)

IndicationStatusPhase
DBCOND0109667 (Prognostic Stage IV Breast Cancer AJCC v8)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT05269381Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid TumorsTreatment